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ABSTRACT: The natural healing process for tendon repair is
associated with high upregulation of collagen type III, leading to
scar tissue and tendon adhesions with functionally deficient
tendons. Gene delivery systems are widely reported as potential
nanotherapeutics to treat diseases, providing a promising approach
to modulate collagen type III synthesis. This work investigates a
proof-of-concept four-arm cationic polymer-siRNA polyplex to
mediate a transient downregulation of collagen type III expression
in a tendon cell culture system. The tendon culture system was first
supplemented with TGF-β1 to stimulate the upregulation of
collagen type III prior to silencing experiments. The four-arm
poly[2-(dimethylamino) ethyl acrylate] (PDMAEA) polymer was
successfully synthesized via RAFT polymerization and then mixed
with siRNA to formulate the PDMAEA-siRNA polyplexes. The formation of the polyplex was optimized for the N:P ratio (10:1) and
confirmed by agarose gel electrophoresis. The size and solution behavior of the polyplex were analyzed by dynamic light scattering
and zeta potential, showing a hydrodynamic diameter of 155 ± 21 nm and overall positive charge of +30 mV at physiological pH. All
the polyplex concentrations used had a minimal effect on the metabolic activity of cultured cells, indicating good biocompatibility.
The dose and time effects of the TGF-β1 on collagen type III gene expressions were analyzed by qPCR, showing an optimal dose of
10 ng mL−1 TGF-β1 and 3-fold increase of COL3α1 expression at 48 h in cultured tenocytes. The PDMAEA-siRNA polyplex
concept observed a limited yet successful and promising efficiency in silencing collagen type III at 48 h compared to PEI-siRNA.
Therefore, this concept is a promising approach to reduce tissue scarring and adhesion following injuries.
■ INTRODUCTION
Injuries to tendon tissues are a common musculoskeletal
problem that can result in severe pain, reduced mobility, and
diminished quality of life in a certain patient population.
Tendon injuries can arise from sudden tendon rupture or can
be chronic in nature, which is widely known as tendinop-
athy.1−3
Tendon rupture can be caused by acute mechanical
overloading, whereas tendinopathy occurs when the tissue is
exposed to chronic overuse or in age-related tissue
degeneration conditions.4 When injuries occur, the natural
healing process is complex and varies in clinical outcomes
based on the anatomical location of the tendon tissue.
Furthermore, owing to the avascular nature of tendon tissue,
the natural healing process is relatively slow and disordered
resulting in a wide range of changes at both cellular and
molecular levels. Typically, the wound healing process
comprises three overlapping phases. These are the inflamma-
tory phase, proliferative phase, and tissue remodeling.5,6
The management of cases with minor injuries could be
relatively straightforward; often, a combination of moderate
rest and/or medical interventions may be sufficient. In other
cases, the management poses greater challenges, which may
require advanced therapies. Several approaches have been
investigated to augment the healing process, namely, the use of
biologics (growth factors, cells therapy, siRNA) or implantable
materials (scaffolds).7,8 One of the major challenges is the
limited accessibility to human tendon tissues to assess the
clinical benefit of these new therapies. Consequently, studies
often rely on using animal models, and equine is one of
them.9,10
As mentioned earlier, various cellular and molecular changes
occur during the natural healing process.11,12 One of the key
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features following tendon injuries is the formation of a scar
tissue (disorganized collagen fibers with mature fibroblast
cells).1−3 Williams et al. studied the histological appearance
and composition of a scared tendon tissue and compared to
that of a healthy tendon, using equine superficial flexor
tendon.13,14 Results showed that the cell-to-matrix ratio was
increased in the scar tissue. Moreover, they reported a change
in the type of collagen. In normal tendon tissue, aligned
collagen type I is the most abundant protein, which constitutes
95% of the tissue. In contrast, in the reparative scar tissue, a
substantial increase in the quantity of disorganized collagen
type III was observed. This increase in collagen type III may
lead to a weaker tensile strength when compared to that of a
normal tissue. Other studies conducted in human subjects have
reported similar significant changes in collagen type III
concentration at the site of injury, but no significant changes
in collagen type I was observed.15−17
Endogenous expression of growth factors is understood to
orchestrate the wound healing process. Both insulin-like
growth factor-I (IGF-I) and transforming growth factor-beta1
(TGF-β1) seem to play a pivotal role in the healing process, in
particular on the expression of collagen types I and III.11
Dahlgren et al. studied the temporal expression of these
endogenous growth factors in equine flexor tendons following
collagenase induced lesion.18 The result of their study showed
an increase in message levels for TGF-β1 in 1 week and IGF-I
in 4 weeks. Similarly, message levels for both collagen types I
and III were increased by week one and remained high for
further 8 weeks.18 Others have used exogenous growth factors
to bolster the wound healing process by enhancing cellular
expression of collagen. Nonetheless, it is plausible that in cases
where the expression of collagen type III (disorganized smaller
fibers) is exceeding and remains at a high undesirable level in
the regenerative phase of healing process may lead to inferior
mechanical properties, scar tissue formation, and/or tendon
adhesion.13,18−21 Therefore, discrete control and transient
regulation of collagen type III expression during the wound
healing process may be more desirable as a new therapeutic
approach.
Several new approaches have been investigated to
manipulate the concentration of collagen types and morphol-
ogy of collagen fibers by targeting messenger RNA (mRNA).
One way to control expression of collagen type III is by
upregulating microRNA (miRNA) levels. Millar et al. studied
miRNA29a expression in both in vitro tenocyte culture and in
vivo models.22,23 They showed that miRNA29a is able to
regulate both IL-33 function and collagen type III synthesis.
Furthermore, interleukin-33 (IL-33) plays an important role in
the transition from type I to type III collagen synthesis in early
stages of tendon remodeling. Downregulation of miRNA29a
was sufficient to enhance collagen type III synthesis. In
addition, small interfering RNA (siRNA) and siRNA-mediated
silencing have been developed to target the gene of interest.
For example, patisiran (Onpattro, Alnylam) is an FDA-
approved siRNA-based treatment used in the treatment of
polyneuropathy in patients with hereditary transthyretin-
mediated amyloidosis, paving the way for the use of siRNA
for treatment of other conditions including tendon-related
disorders.24,25
Notwithstanding the efficacy of siRNA treatment, admin-
istration of naked siRNA is challenging as it can be degraded in
the bloodstream or unable to cross cell membranes and may
pose risk to induce an immunogenic response.26,27 With that in
mind, numerous siRNA delivery systems have been developed,
including lipid-based and polymer-based systems.28−30 The
latter system is more accessible for customization and
optimization as its components can be defined and adjusted,
using a variety of starting materials and polymerization
techniques.
Herein, we synthesized a new synthetic four-arm poly[2-
(dimethylamino) ethyl acrylate] (PDMAEA) polymer using
reversible addition-fragmentation chain transfer (RAFT).31
The synthesized polymer was mixed with custom-designed
siRNA to target collagen type III to form polyplexes (a mixture
of condensed polymer and siRNA) in nanometer-sized range.
Scheme 1. Schematic representation showing the chemical synthesis of a four-arm DDMAT-PDMAEA. The synthesis of a four-
arm star-shaped PDMAEA polymer from DMAEA monomers using RAFT polymerization techniques. A four-arm DDMAT
was used to prepare the star-shaped PDMAEA. Polymerizations were carried out in 2-butanone at 70 °C in the presence of
thermal initiator AIBN
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In order to investigate the toxicity profiles of these polymers
and polyplex, cultured equine tenocytes were treated with
various concentrations of the polyplexes. We then induced
overexpression of collagen type III in the cultured cells using
TGF-β1 growth factor at optimal concentration, prior to
treating the cells with the polyplexes. Our result showed that
the new polymer is well tolerated by the cells when compared
to standard PEI, and the collagen type III message level was
suppressed at 48 h of post-treatment compared to 72 h when
PEI polyplex was used. This study shows a proof of concept to
use a new and safe siRNA-based approach as a potential
treatment by regulating the collagen type III synthesis in
tendon-related disorders.
■ RESULTS
In this study, the aim was to use PDMAEA as the delivery
vector in the format of a polyplex for the delivery of specific
siRNA to knockdown the expression of COL3α1 in TGF-β1
stimulated tenocytes as shown in Scheme S1. A four-arm
cationic DMAEA polymer was successfully synthesized with a
molecular weight of ∼10 kDa using our previously established
protocol (Scheme 1).31
Characterization of PDMAEA-siRNA Polyplexes. Prior
studies demonstrated the significance of particle size, surface
charge, and method of preparation of polyplexes in gene
transfection.32−35 Previously, we optimized the polyplexation
of PDMAEA polymers with model dsDNA.31 The results of
this study showed that a N:P ratio of 10:1 is ideal (the ratios of
moles of the amine groups of cationic polymers to those of the
phosphate ones of DNA) for the formation of a stable polyplex
with hydrodynamic diameters of 155 ± 21 and positive zeta
potential values at a relevant pH range. Hence, in this work, a
N:P ratio of 10:1 for the PDMAEA-siRNA polyplexes was
used. Characterization of the polyplex was carried out using
agarose gel electrophoresis to confirm the polyplex formation.
Figure 1A demonstrates the polyplex formation at a 10:1 N:P
ratio (lane 2) compared to free siRNA in the absence of the
PDMAEA polymer (lane 1). Full-length agarose gel electro-
phoresis is shown in Figure S2. Figure 1B demonstrates the
well-defined hydrodynamic diameter size and positive zeta
potential values of the PDMAEA-siRNA polyplexes measured
at pH 5.4, 6.4, and 7.4, in the pH range that occur during
intracellular uptake. Particle sizes are calculated from the
intensity, number, and volume distributions. The number and
volume distribution are marginally smaller than the intensity
distribution but show a similar trend across all measured pH
values.
Calculated mean sizes for the PDMAEA-siRNA polyplex
were 155 ± 21, 47 ± 7, and 82 ± 17 nm for intensity, number,
and volume distributions respectively. The mean zeta potential
values are +41.6 ± 2.2, +38.9 ± 1.6, and +29.7 ± 1.1 for pH of
5.4, 6.4, and 7.4 respectively. These variations between
intensity and number distributions are expected from DLS
measurement owing to the presence of heterogeneous polyplex
populations. Notably, the positive zeta potential value is
greater at pH 5.4 compared to pH 7.4, likely due to the higher
protonation of the amine groups on the side chains of the
polymer at a lower pH value. Nonetheless, the size
distributions and zeta potential values of the PDMAEA-
siRNA polyplexes are within the range of reported values for
polyplexes employed in transfection experiments.
Effect of the PDMAEA and PEI Polymers and
PDMAEA-siRNA and PEI-siRNA Polyplexes on Cultured
Tenocytes. The results in Figure 2A,B show the cytotoxicity
of PDMAEA and PEI polymers as well as PDMAEA and PEI-
siRNA polyplexes, as measured by the standard MTS assay, in
cultured equine tenocytes, at a range of polyplex concen-
trations of 0.25, 2.5, 5, 10, 15, 20, 25, 30, and 50 μM and for
the incubation times of 24, 48, and 72 h. All examined
PDMAEA polymer and polyplex concentrations had no or
minimal effects on the metabolic activity of the cultured cells
compared to untreated control cells. Similarly, different
incubation times of the cells with the PDMAEA polymer or
polyplexes resulted in no significant changes in cellular
metabolic activity. The results indicated that both PDMAEA
and PDMAEA-siRNA polyplexes had low cytotoxicity and
were well tolerated by the cultured equine tenocytes. In
contrast, the examined PEI and PEI-siRNA polyplexes had
Figure 1. Confirmation of PDMAEA-siRNA polyplex formation and measurements of solution behavior. (A) Agarose gel electrophoresis showing
free siRNA in the absence of the PDMAEA (lane 1) and PDMAEA-siRNA polyplexes (lane 2) at 10:1 N:P ratios. Note that agarose gel shown in
(A) has been cropped, and the full-length version of the agarose gel is available in Figure S2. (B) Hydrodynamic diameter measured by dynamic
light scattering (DLS). On the left Y-axis, the gray line, black line, and black dotted columns represent intensity, number, and volume distributions,
respectively. Black dots above columns correspond to the zeta potential of the polyplexes measured at pH 5.4, 6.4, and 7.4. All data are presented as
mean ± SD (n = 3). L (lane); nm.d (diameter in nanometers); mV (millivolts).
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significant (p < 0.0001) cytotoxic effects on the cultured
equine tenocytes, especially in concentrations ranging from 2.5
to 50 μM and regardless of the incubation time.
Collagen Type III Expression Levels Remain Constant
with Serial Passaging of Equine Tendon Cells. The effect
of serial passage on its expression in equine tendon cells was
determined to ensure that collagen type III gene expression
levels did not decrease over time in culture. COL3α1 was
expressed at high levels at all passages between cells isolated
from different donors, although they were variable. No
significant differences in COL3α1 expression were observed
at any passage between P0 and P10 (Figure 3A). In contrast,
COL1α1 has a higher expression at P0 than it does at P3
through to P10 (Figure 3B). However, COL1α1 levels do not
significantly change beyond P3 with the further passage.
TGF-β1 Treatment. TGF-β1 was used to upregulate the
synthesis of collagen type III in cultured equine tenocytes. In
order to optimize the dose of TGF-β1, cultured tenocytes were
supplemented with different concentrations of TGF-β1 from
0.5 to 50 ng mL−1 for 24 h. The results in Figure 4A show the
relative expression of COL3α1 as measured by qPCR. The data
showed that the relative expression of COL3α1 (fold change)
increases with increased concentration of TGF-β1 up to a 3-
fold increase at 10 ng mL−1. However, at higher concentrations
of 25 and 50 ng mL−1 TGF-β1, COL3α1 exhibits lower fold
increases of 2.5- and 1.5-fold, respectively. Therefore 10 ng
mL−1 was used in the following experiments.
In addition, to study the fold changes in COL3α1 expression
as a function of time, we examined the fold change of COL3α1
in the cultured tenocytes, using a concentration of 10 ng mL−1
and incubation times of 24, 48, and 72 h. The results in Figure
4B demonstrate that COL3α1 expression increased for all time
points in samples supplemented with TGF-β1 compared to
samples without TGF-β. Furthermore, the maximum COL3α1
expression occurred after 48 h of TGF-β1 stimulation.
PDMAEA-siRNA Transfection of Equine Tenocytes.
Next, the siRNA-mediated knockdown of COL3α1 in the
TGF-β1 stimulated equine tenocytes using PDMAEA-siRNA
polyplex was investigated. Cells with no added TGF-β1 and
PDMAEA-siRNA random polyplex were used as a negative
control, whereas PEI-siRNA COL3α1 was used as a positive
control. The results in Figure 5 show the fold change in
Figure 2. Effect of PDMAEA and PEI polymers and PDMAEA-siRNA and PEI-siRNA polyplexes on metabolic activity of cultured equine
tenocytes. Adult equine tenocytes were treated with different concentrations of PDMAEA or PEI (A) and PDMAEA or PEI-siRNA polyplexes (B),
and metabolic activity was measured by the MTS assay at 24, 48, and 72 h post-treatment. All data are presented as mean ± SD (n = 3,
independent cell culture replicates), as a percentage of metabolic activity of cultured equine tenocytes normalized to untreated control cells (dashed
line). Statistical analysis two-way ANOVA with Tukey’s multiple comparison test was applied for displaying significant differences of the doses in
between the PDMAEA and PEI polymers or PDMAEA or PEI-siRNA polyplexes. ns: not significant (p = 0.1234), **p = 0.0021, ***p = 0.0002,
****p < 0.0001. COL3α1 (collagen 3α1); PDMAEA (polydimethylaminoethyl acrylate); siRNA (small interfering RNA); PEI
(polyethyleneimine).
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COL3α1 as measured by PCR after 48 (Figure 5A) and 72 h
(Figure 5B) compared to the non-transfected control cells
cultured in the absence of TGFβ1. It can be seen that the
target PDMAEA-siRNA COL3α1 polyplex mediated a
reduction in fold change of 2 in COL3α1 expression compared
to the non-target PDMAEA-siRNA-random after 48 h,
providing a positive insight into the potential of the polyplex.
In contrast, the target PEI-siRNA COL3α1 polyplex showed
no reduction compared to the non-target PDMAEA-siRNA
random. However, at 72 h, the target PDMAEA-siRNA
COL3α1 had no silencing effect compared to non-target
PDMAEA-siRNA random, but the target PEI-siRNA COL3α1
polyplex showed a fold change of 2 reduction compared to the
non-target PDMAEA-siRNA random COL3α1. Nonetheless,
the overall fold increase of COL3α1in TGFβ1 treated versus
untreated cells was higher at 48 h compared to 72 h.
■ DISCUSSION
The overall aim of this study was to establish a simple
formulation based on a well-defined four-arm cationic polymer
for the delivery of siRNA. The intent was to target and
suppress collagen type III synthesis in an ex vivo tenocyte
culture. In this study, a four-arm PDMAEA cationic polymer
with a molecular weight of approximately 10 kDa was chosen.
This was based on a previously optimized system where we
demonstrated that this specific molecular weight was able to
readily form polyplexes with dsDNA molecules and reduce
cytotoxicity compared to its linear counterpart or “gold-
standard” transfecting agent PEI.31 We also demonstrated that
the four-arm PDMAEA polymer could form a polyplex with
siRNA at a relatively low N:P ratio, likely due to the lower
steric hindrance in the open four-arm structure. The
hydrodynamic diameter of the formed polyplexes was
investigated at a pH range that resembles the changes that
occur in the cytosol. All concentrations examined of the
PDMAEA polymer successfully resulted in polyplex formation
with the siRNA. The resulting particles had an average
hydrodynamic diameter of 155 ± 21 nm. Previous reports
suggested that particle sizes less than 200 nm could be
efficiently taken up by cells.36−38 Similarly, the presence of a
Figure 3. Collagen type III and I expression levels in serial passaging
of equine tendon cells. Box and whisker plots of collagen expression
over serial passaging (P0 to P10) in three independent lines of equine
tendon cells. (A) COL3α1shows no significant differences in
expression between any passages. (B) COL1α1expression at P0 is
significantly higher than at P3 through to P10 as indicated by the
asterisk. However, after P3, there is no significant change in COL1α1
expression with the further passage. Statistical significance was tested
using linear regression analysis using R (v.3.5.2).
Figure 4. Dose and time effects of TGF-β1 treatment on collagen
type III expression in cultured equine tenocytes. (A) Adult equine
tenocytes were treated with different concentrations of TGF-β1 for 24
h, and COL3α1 mRNA levels were analyzed by qPCR. (B) Adult
equine tenocytes were treated with 10 ng mL−1 TGF-β1, and
COL3α1 mRNA levels were analyzed by qPCR at 24, 48, and 72 h
after stimulation. Data in panels (A) and (B) are shown as relative
expression (fold change) compared to untreated cells. The dashed
line represents the baseline equal to 1 calculated with DCt values from
untreated cells. 18S housekeeping gene expression was used to
normalize the data. Data are presented as mean ± range. TGF-β1
(transforming growth factor-β1); +TGF-β1 (adult equine tenocytes
treated with transforming growth factor-β1); -TGF-β1 (untreated
adult equine tenocytes).
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positive surface charge is reported to affect cellular uptake.39,40
The zeta potential of the polyplexes at relevant pH values
above +20 mV is an indication of colloidal stability.
Previous studies showed a “tradeoff” relationship between
transfection efficiency and cytotoxicity of gene delivery vectors.
For example, polyethyleneimine (PEI), a non-viral vector, is
reported to produce high transfection efficiencies but
demonstrates significant cellular toxicity, as shown in the
present work per results in Figure 2A,B. In contrast, we
demonstrated that the PDMAEA polymer profile was well
tolerated in cultured equine tenocytes at different concen-
trations and incubation times.31 Nonetheless, the biocompa-
tibilities of both the PDMAEA and PDMAEA-siRNA
polyplexes were re-examined. There was no apparent
cytotoxicity of the PDMAEA or PDMAEA-siRNA polyplexes
in cultured tenocytes, rendering it a good candidate for gene
targeting. The biocompatibilities of the PDMAEA and
PDMAEA-siRNA polyplex were illustrated at a range of
concentrations (including the concentration used in trans-
fection). The MTS standard metabolic assay was used, which is
often used to measure the cytotoxicity of molecules in cultured
cells.41 The results showed that the polymer and the polyplex
concentrations used had minimal cytotoxicity toward cultured
cells over prolonged incubation times up to 72 h. Therefore,
the data indicate that both the PDMAEA and the PDMAEA-
siRNA polyplex were well tolerated by the tenocytes and can
be used as a safe proof-of-concept gene delivery vector. In
contrast, the obtained results demonstrated that the metabolic
activity of the cultured tenocytes was significantly hampered by
all the tested concentrations of PEI polymer, except for the
dose used in transfection (0.25 μM), which did not
significantly reduce the metabolic activity compared to
PDMAEA polymer at the same concentration. However, the
effect on the metabolic activity of the PEI-siRNA polyplexes at
transfection concentration (0.25 μM) was found to be
significant at 24 and 48 h of incubation times, but not at 72
h, suggesting a potential recovery of the cultured tenocytes in
longer periods of incubation. Similar to PEI polymer, the rest
of the tested PEI-siRNA polyplex concentrations showed
cytotoxic effects in the cultured tenocytes. Therefore, the
results suggest that PDMAEA-siRNA polyplexes are a good
candidate for gene delivery and allow for the use of a wide
range of polymer concentrations, whereas PEI-siRNA poly-
plexes should be used at lower concentrations to avoid a
greater cytotoxic effect.
Next, collagen type III silencing mediated by the polyplex
was investigated. However, gene expression in tendon cells has
been shown to change with culture42,43 and can change rapidly
from the expression levels found in the native tissue.44 We,
therefore, confirmed that COL3α1 expression levels did not
decline over time in culture and that the use of high passage
cells in these studies would still give applicable results. We
found that, while there was variation in COL3α1 expression at
each passage, it was highly expressed in all donor cell lines at all
passages and that there is no significant difference in COL3α1
expression at any passage between passage 0 and passage 10 in
equine tenocytes. This is in contrast to a previous study on
human tenocytes that showed that COL3α1 expression
increased with passage.42 We also demonstrate that COL1α1
levels drop significantly between passage 0 and passage 3 but
remain constant until passage 10. Furthermore, we previously
demonstrated that there is no significant difference in collagen
gel contraction and response to inflammation in equine tendon
cells used between passages 4 and 11.45 Therefore, although
the effect on collagen knockdown was performed in high
passage cells in this current study, we believe that the results
provide an accurate in vitro model.
Ideally, we would have chosen to use tenocytes isolated from
rupture sites that are reported in the literature to produce more
collagen type III than cells isolated from healthy tendon
tissue.46 However, in the absence of suitable donor tissue, we
increased the synthesis of collagen type III using TGF-β1.47
Since this was a new experiment, we first investigated the effect
of concentration and incubation time of TGF-β1 in cultured
tenocytes. Using PCR to calculate the relative expression of
COL3α1, we were able to determine the effect of different
doses of TGF-β1. From there, we determined the optimal
concentration and length of application of TGF-β1 which
Figure 5. PDMAEA-siRNA polyplex mediated silencing of COL3α1
in cultured equine tenocytes. Adult equine tenocytes were treated
with 10 ng mL−1 TGF-β1 for 24 h and subsequently with PDMAEA-
siRNA polyplexes in different conditions. COL3α1 mRNA levels were
analyzed by qPCR at (A) 48 and (B) 72 h post-transfection. Data in
panels (A) and (B) are shown as relative expression (fold change)
compared to untreated cells. The dashed line represents the baseline
equal to 1, calculated with DCt values from untreated cells. 18S
housekeeping gene expression was used to normalize the data. Data
are presented as mean ± range. TGF-β1 (transforming growth factor-
β1); +TGF-β1 (adult equine tenocytes treated with transforming
growth factor-β1); -TGF-β1 (untreated adult equine tenocytes),
COL3α1 (collagen 3α1); PDMAEA (polydimethylaminoethyl acryl-
ate); siRNA (small interfering RNA); PEI (polyethyleneimine).
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induced maximal COL3α1 gene expression. The conditions
were optimized for both PDMAEA and PEI and to allow for
direct comparisons with the PCR assays. Both polymers have
an equal amount and concentration of the therapeutic siRNA
and were tested under the same conditions.
Next, we demonstrated that the PDMAEA-siRNA polyplex
could specifically silence COL3α1 gene expression in TGF-β1
boosted tenocyte culture conditions. As measured by PCR, the
fold change in the COL3α1 silencing effect was observed only
for the polyplex formed with the target PDMAEA-siRNA
COL3α1. However, the silencing effect was more apparent at
48 h compared to 72 h, likely since the highest induction of
COL3α1 synthesis was achieved at 48 h by TGF-β1. We also
noted that PEI-siRNA polyplex mediated silencing was greatest
at 72 h. The two polymers have different transfection efficacies
where PEI achieves its greatest silencing at 72 h, but our
polyplex achieves it at 48 h without cytotoxicity, as confirmed
per the MTS assay and shown in Figure 2A,B. Although
messenger RNA analysis by qPCR has been widely used as a
tool to assess gene expression in tendon tissue engineering,
future work could benefit from protein or other analysis to
provide other quantitative methods for this study.
■ CONCLUSIONS
This study provides a successful proof-of-principle that the
PDMAEA polymer can be used for delivery of siRNA to target
collagen type III overexpression with potential application in
tendon injuries. Optimizing the polyplex system can further
provide a more comprehensive understanding of this technique
as a specific silencing system. For example, the collagen type III
knockdown was performed on tenocytes derived from one
individual animal, and therefore, further biological replicates
would provide greater insight into the effectiveness of this
approach. Our polyplexes are well tolerated with increased
concentrations suggesting that repeated doses might be
possible. As tendon is avascular, systematic absorption might
be less favorable in comparison to direct local injection with
the aid of ultrasound scanning. Furthermore, the effect on
collagen type III silencing could be studied further by
determining the effect on COL3α1 protein expression and
localization. Additionally, determining the effect of applying a
short pulse of TGF-β1 versus a sustained exposure and the
effect of TGF-β1 over longer periods of time would provide a
deeper comprehension into the potential silencing mechanism.
Further work would be required to determine the impact on
the ratio of collagen types III and I following COL1α3
knockdown. Following a tendon injury, there may also be an
influx of cells from outside the tendon, for example, bone-
marrow-derived stromal cells. Future work should aim to
investigate whether this technology can also be used to reduce
COL1α3 expression in such cell types. Studies on the dose
duration and efficacy of uptake can also be examined as future
progress from this work. Further studies will also investigate
the development of the injectable and controlled-release
system to deliver PDMAEA-siRNA polyplex over a prolonged
period of time in order to control tendon adhesion and tissue
scarring. This could be carried out by loading or encapsulating
the polyplex into polymeric nanoparticles composed of
degradable polymers, using standard double emulsion
techniques, in which the rate of the polymer degradation can
be used to tune the release profile.48
■ MATERIALS AND METHODS
Chemical and Biological Reagents. Four-arm star-
shaped polydimethylaminoethyl acrylate (PDMAEA, Mn:
10000, Mw: 12000) was synthesized by reversible addition-
fragmentation chain transfer (RAFT) as reported previously31
and used as the transfecting agent. Collagen type III siRNA
(denoted as siRNA COL3α1, Mw 13273, 10 nmol, sense
strand 5′-3’ CAUCACAUAUCACUGCAAA [dT][dT], anti-
sense strand 5′-3’ UUUGCAGUGAUAUGUGAUG [dT]-
[dT]) sequences specific for equine tendon cells were
purchased from Sigma-Aldrich. 18S ribosomal RNA (18Sr
RNA) primer sequences were used as a housekeeping gene. A
random siRNA sequence (denoted as siRNA random) to the
siRNA COL3α1 was also purchased from Sigma-Aldrich and
used as a negative control. The CellTiter 96 AQueous One
Solution Cell Proliferation Assay (MTS assay, Promega, U.K.),
branched polyethyleneimine (denoted as PEI, 10000 Da-
branched, Sigma), agarose (Sigma), Tris base (Sigma), acetic
acid (Sigma), EDTA (Sigma), MTS (Promega), bovine serum
albumin (BSA, Fisher), Dulbecco’s modified Eagle medium
(DMEM, Fisher), fetal calf serum (FCS, Fisher), trypsin
(Fisher), penicillin−streptomycin solution (Fisher), L-gluta-
mine (Fisher), HEPES (Bioreagent, 99%, Sigma), Tri Reagent
solution (Invitrogen), 1-bromo-3-chloropropane (Sigma),
isopropanol (Sigma), ethanol (Sigma), and gelatine solution
(Sigma) were used as received. The DNA-free DNA Removal
Kit (Thermo Fisher), High-Capacity cDNA Reverse Tran-
scription Kit (Thermo Fisher), and SYBR Green JumpStart
Taq ReadyMix (Sigma) were used according to manufacturers’
guidelines. Phosphate buffered saline tablets (PBS, Fisher
Chemical) were used at 1× concentration in ultrapure water
for cell culture purposes. Ethidium bromide was used at a
concentration of 6 μg mL−1 in 1× TAE for agarose gel
electrophoresis. Paraformaldehyde (Sigma) was used at 3%
concentration for immunocytochemical techniques. Adult
horse tendon cells (received at passage 7) were provided by
Dr. D. Guest (Animal Health Trust, U.K.) and were grown as
monolayers and expanded to passage 9 for the experiments.
Human recombinant TGF-β1 was purchased from Peprotech.
Preparation of PDMAEA-siRNA Polyplexes. siRNA
solution was added to a microcentrifuge tube at a final
concentration of 132 μg mL−1 in HEPES buffer (100 μL, 30
mM, pH 7.4). Calculated amounts of the PDMAEA were
prepared in 100 μL of HEPES buffer (30 mM, pH 7.4) and
added to siRNA to form polyplex at a N:P ratio of 10:1. The
polyplex solution was diluted to 1 mL with HEPES buffer
resulting in a final siRNA concentration of 13.2 μg mL−1 and a
final PDMAEA concentration of 0.6 mg mL−1. Solutions were
mixed by vortexing for 15 s and then allowed to equilibrate for
30 min at room temperature before characterization.
Agarose Gel Electrophoresis. PDMAEA-siRNA poly-
plexes (8 μL of the sample with 2 μL of 1× loading dye) were
loaded on a 1.5% agarose gel in Tris-acetate−EDTA (TAE, pH
8.0). Electrophoresis was performed at 80 V for 40 min in a
Mini-Sub cell system (Bio-Rad Laboratories). The gel was later
submerged in 0.006% ethidium bromide solution for post-cast
staining for 1 hour. Bands were visualized and photographed
using a ChemiDoc-It 2810 imager (U.V.P, USA). Data were
collected and analyzed using the software provided.
Dynamic Light Scattering. The size and dispersity of the
PDMAEA-siRNA polyplexes were determined by dynamic
light scattering. 1 mL of PDMAEA-siRNA polyplex (prepared
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in 30 mM HEPES, pH 7.4) was added to a cuvette, and the
samples were examined using a Zetasizer Nano ZS (Malvern,
U.K.) equipped with a He-Ne laser (4 mW, 633 nm). The
measurement angle was set at 173° backscattered. The size
distribution of the scattering polyplexes was determined and
reported as average light intensity, volume, and number of
polyplexes.
Surface Charge Measurement (Zeta Potential). The
surface charge of the PDMAEA-siRNA polyplexes was
measured by a Zetasizer Nano ZS (Malvern, U.K.) using a
DTS 1060 folded capillary cells. The measurements were
recorded in 10 mM HEPES buffer solution at pH 5.5, 6.5, and
7.4. The zeta potential measurements are reported as mean
value ± standard deviation from three measurements of at least
20 runs per measurement.
Cells Metabolic Activity Assay. Adult equine tendon
cells were isolated, as described previously,49 from healthy
adult horse tendons with the approval of the Animal Health
Trust Ethical Review Committee (AHT_02_2012). These
cells were analyzed previously for their gene and protein
expression,45,49 ability to contract a collagen gel,50 and the
effect of gene knockdown.51 Tendon cells were cultured in
Dulbecco’s modified Eagle medium (DMEM) supplemented
with 10% heat-inactivated fetal calf serum (FCS), 1% L-
glutamine, and 1% penicillin−streptomycin (PS). All cell
cultures were maintained in a humidified atmosphere
containing 5% CO2 at 37 °C. Cells at passage 9 were seeded
at 10000 cells/0.32 cm2 (96-well plates) and allowed to adhere
for 24 h before the experiment began. The PDMAEA or PEI-
siRNA polyplexes were freshly prepared as described
previously at different concentrations of the PDMAEA or
PEI polymer, ranging from 0.25, 2.5, 5, 10, 15, 20, 25, 30, and
50 μM. The polymer and polyplexes were incubated for 24, 48,
and 72 h. To analyze the metabolic activity of the equine
tenocytes, 10% MTS reagent was used according to the
manufacturer’s protocol. After 1 h of incubation, the
absorbance was read at 490 nm in a microplate reader
(Omega). For PEI containing samples, the supernatant was
removed and transferred to a fresh plate before absorbance was
read. All the data are presented as a percentage of cell
metabolic activity compared to non-treated cells.
Collagen Type III Expression Level in Serial Passages
of Equine Tendon Cells. Three independent tendon cell
lines were cultured from three different horses and RNA
extracted at every passage to determine the expression of
COL1α1 and COL3α1 using qPCR.
TGF-β1 Treatment. Adult equine tendon cells (passages
7−9) were cultured in six-well plates at a density of 600000
cells/9.6 cm2. To determine the optimal stimulation dose of
TGF-β1 for collagen type III upregulation, different concen-
trations (0.5, 1, 10, and 25 ng mL−1) were prepared in PBS
(1×) containing 0.1% BSA and added to the cell culture
medium. Cells were then incubated for 24 h prior to
harvesting, and COL3α1 levels were analyzed by qPCR. For
transfection efficiency analysis, cells were cultured in the same
conditions as described previously but using 10 ng mL−1
concentration of TGF-β1. Cells were then harvested after 24,
48, and 72 h, and COL3α1 levels were analyzed by qPCR.
RNA Extraction and cDNA Synthesis. Adult equine
tenocytes were directly lysed with 1 mL of Tri-reagent per well
according to the manufacturer’s protocol and preserved at −80
°C until analysis. After thawing, 100 μL of 1-bromo-3-
chloropropane were added to each sample. After gently
shaking, the tubes were incubated at room temperature for
10 min and then centrifuged at 4 °C for 20 min, in order to
separate the RNA to the aqueous phase, which was then
transferred to fresh tubes. 500 μL of isopropanol was added to
each tube, vortexed, and incubated for 10 min at room
temperature. Tubes were then centrifuged at 4 °C for 20 min,
and the supernatant was discarded. RNA pellets were washed
with 1 mL of 70% ethanol. After centrifugation at 4 °C, ethanol
was discarded, and pellets were left to dry in air for 10 min
before solubilizing the RNA in 20 μL of nuclease-free water.
RNA was then treated with Ambion DNA-free DNA Removal
Kit (Life Technologies, Paisley, U.K.) according to the
manufacturer’s instructions. RNA purity was assessed using a
Nanodrop 1000 spectrophotometer (Thermo Fisher). RNA
samples with values below 1.8 at a ratio of 260/280 were
excluded. First-strand complementary DNA (cDNA) was
made from 1 μg of RNA using High-Capacity cDNA Reverse
Transcription Kit on a PTC-100 thermal cycler (Bio-Rad)
using the following protocol: 10 min at 25 °C, 120 min at 37
°C, and 5 min at 85 °C. 200 ng of synthesized cDNA in a 20
μL reaction volume was used in a quantitative real-time
polymerase chain reaction (qRT PCR).
Quantitative PCR. Primer sequences used in the qPCR are
reported as follows: 18S rRNA gene forward CCCAGTGA-
GAATGCCCTCTA, reverse TGGCTGAGCAAGGTGT-
T A T G ; C O L 3 α 1 g e n e f o r w a r d
C T G G T G C T A A T G G T G C T C C T , r e v e r s e
TCTCCTTTGGCACCATTCTT. Synthesized cDNA was
amplified using an SYBR Green JumpStart Taq ReadyMix
master mix, and qPCRs were performed on a Rotor-Gene Q
2plex Platform (Qiagen). All qPCR reactions were performed
in duplicate. PCR cycle conditions were set as follows: initial
denaturation at 94 °C for 2 min followed by 40 cycles of 94 °C
for 15 s and 60 °C for 15 s. At the end of the program, the
temperature was reduced to 60 °C and then gradually
increased by 1 °C increments up to 95 °C to produce a
melt curve. Gene expression was normalized to the 18S rRNA
gene expression levels using the threshold cycle (Ct) − relative
quantification method (2−ΔΔCt). The Ct values of the 18S gene
did not change between the control and treated samples. Data
are presented as a fold change compared to unstimulated cells.
In all reactions, a standard curve including five dilutions of
known cDNA was generated to ensure highly efficient product
amplification. R2 of all reactions was 0.98−0.99.
PDMAEA-siRNA Transfection of Equine Tenocytes.
Adult equine tenocytes were seeded into six-well plates at a
density of 600000 cells/9.6 cm2 and allowed to adhere for 24
h. Cell culture media were then supplemented with TGF-β1 at
10 ng mL−1 concentration for 24 h. The PDMAEA-siRNA
polyplex was prepared as described before and added to the
wells to achieve a final siRNA concentration of 50 nM (this
equals to 4.5 μM polyplex concentration). Cells were then
harvested, RNA was extracted, and COL3α1 and 18S mRNA
levels were analyzed by qRT PCR. Control cells with no TGF-
β1 and cells treated with PDMAEA-siRNA random were used
as a negative control, whereas PEI-siRNA was used as a
positive control. All experiments were performed in duplicate.
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